Roche’s efforts to break into the lucrative obesity market haven’t abated. The pharma giant sealed the largest deal in the space earlier this year when it announced a collaboration with Zealand Pharma ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...

Investing.com -- Wells Fargo has initiated coverage of Zealand Pharma (NASDAQ: ZEAL) with an Overweight rating and a DKK 650 ...

Dealmaking in Europe’s life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength ...

Forward-Looking Statements Zealand has made significant progress against its 2024 priorities, particularly with the Petrelintide Phase 1b data and the Survodutide Phase 2 MASH trial results. The ...

Petrelintide, amylin analog. In the first half of 2026, Zealand Pharma expects to report topline results from the Phase 2 ZUPREME-1 trial and complete the Phase 2 ZUPREME-2 trial with petrelintide.

Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug.